Table 1. Included trials/treatments and important patient characteristics.

Study name or code	Interventions	Number randomised	Week of analysis (primary time point)	Mean age (years)	% Male	% Naïve	Mean disease duration (years)
Induction
GEMINI 1 [29]	PBO	149	6	41.2	62	51	7.1
	VDZ 300 mg IV at week 0 and 2 and every 8 weeks thereafter	225	6	40.1	59	58	6.1
ULTRA 1 [44]	PBO	130	8	38.4	63	100	5.4a
	ADA 160 mg SC at week 0, followed by 80 mg at week 2 and then 40 mg every other week	130	8	37.9	64	100	6.1a
ULTRA 2 [45, 46]	PBO	258	8	41.3	62	59	8.5
	ADA 160 mg SC at week 0, followed by 80 mg at week 2 and then 40 mg every other week	260	8	39.6	57	61	8.1
ACT 1 [27]	PBO	121	8	41.4	60	100	6.2
	IFX 5 mg/kg IV at week 0, followed by 5 mg/kg at 2 and 6 weeks and every 8 weeks thereafter	122	8	42.4	65	100	5.9
ACT 2 [27]	PBO	121	8	39.3	58	100	6.5
	IFX 5 mg/kg IV at week 0, followed by 5 mg/kg at 2 and 6 weeks and every 8 weeks thereafter	120	8	40.5	63	100	6.7
PURSUIT-SC [47]	PBO	331	6	39.0	53	100	6.0
	GLM 200 mg SC at week 0, followed by 100 mg at week 2 and then 100 mg every 4 weeks	331	6	40.0	54	100	6.4
Suzuki, 2014 [49]	PBO	96	8	41.3	72.9	100	7.8
	ADA 160 mg/80 mg	90	8	42.5	67.8	100	7.8
Maintenance
GEMINI 1 [28, 29, 30, 32, 33, 34]	PBO	126	52	40.3	55	63	7.8
	VDZ 300 mg IV every 8 weeks	122	52	41.0	57	59	6.2
ULTRA 2 [45, 46]	PBO	246b	52	40.5	58	87	NR
	ADA 40 mg SC every other week	248b	52	40.5	58	87	NR
ACT 1 [27]	PBO	121b	54	41.4	60	100	6.2
	IFX 5 mg/kg IV every 8 weeks	122b	54	42.4	65	100	5.9
PURSUIT-M [48]	PBO	156	54	40.2	48	100	6.9
	GLM 100 mg every 4 weeks	154	54	39.1	58	100	7.2
Suzuki, 2014 [49]	PBO	96b	52	NR	NR	100	NR
	ADA 40 mg SC every other week	177b	52	NR	NR	100	NR

ADA, adalimumab; GLM, golimumab; IFX, infliximab; IV, intravenously; NR, not reported; PBO, placebo; SC, subcutaneous; VDZ, vedolizumab.

^a Median disease duration.

^b These studies were not rerandomised at maintenance, so the number of patients who responded at the end of induction has been used in this table.